New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride

Abstract: Oral administration of sapropterin hydrochloride, recently approved for use by the US Food and Drug Administration and the European Commission, is a novel approach for the treatment of phenylketonuria (PKU), one of the most common inborn errors of metabolism. PKU is caused by an inherited deficiency of the enzyme phenylalanine hydroxylase (PAH), and the pathophysiology of the disorder is related to chronic accumulation of the free amino acid phenylalanine in tissues. Contemporary therapy is based upon restriction of dietary protein intake, which leads to reduction of blood phenylalanine levels. This therapy is difficult to maintain throughout life, and dietary noncompliance is commonplace. Sapropterin dihydrochloride is a synthetic version of tetrahydrobiopterin, the naturally occurring pterin cofactor that is required for PAH-mediated phenylalanine hydroxylation. In a subset of individuals with PAH deficiency, sapropterin administration leads to reduction in blood phenylalanine levels independent of dietary protein. For these individuals, sapropterin is an effective novel therapy for PKU.

Keywords: sapropterin dihydrochloride, phenylketonuria, phenylalanine, tetrahydrobiopterin

Introduction
Dietary restriction of phenylalanine intake has been the mainstay of therapy for phenylketonuria (PKU), one of the most common inborn errors of metabolism, for the past 50 years. With the recent US Food and Drug Administration (FDA) and European Commission approvals of sapropterin dihydrochloride (Kuvan®; BioMarin Corporation, Tiburon, CA), a new era in PKU treatment has begun. Sapropterin dihydrochloride is a synthetic version of tetrahydrobiopterin, the naturally occurring pterin cofactor, tetrahydrobiopterin (BH₄). In a subset of individuals with PKU, sapropterin treatment substantially reduces blood phenylalanine levels independent of dietary phenylalanine intake. For these so-called “BH₄-responsive” patients, sapropterin therapy provides the benefit of improved disease control and may even eliminate the need for dietary therapy completely in individuals with milder forms of hyperphenylalaninemia.

Biology of phenylketonuria and tetrahydrobiopterin
PKU has an annual incidence of about 1:16,000 births in the US.¹ PKU is caused by recessively inherited mutations in the PAH gene that encodes the enzyme phenylalanine hydroxylase (PAH). PAH is predominantly expressed in liver (but also kidney and pancreas) and catalyzes the irreversible hydroxylation of phenylalanine, an essential amino acid, to tyrosine (Figure 1). PAH is a homotetramer that requires iron and molecular oxygen as well as the unconjugated pterin cofactor, BH₄⁺, for catalytic activity.
BH₄ is synthesized de novo from guanosine triphosphate in several tissues, including liver, but is also recycled after phenylalanine hydroxylation through enzymatically-catalyzed reduction. Inherited deficiency of BH₄ synthesis or recycling enzymes is the cause of hyperphenylalaninemia in approximately 2% of infants detected through newborn screening. Treatment of these children frequently requires chronic oral or parenteral BH₄ administration in addition to dietary phenylalanine restriction.

PAH deficiency leads to accumulation of phenylalanine in all tissues of the body and relative deficiency of tyrosine. Untreated PKU is associated with chronic hyperphenylalaninemia, microcephaly, mental retardation, epilepsy, relative hypopigmentation, growth delay, and eczema. Fortunately, all infants in the US and most Western countries are screened for hyperphenylalaninemia at 24–72 hours of life. Initiation of therapy early in life prevents the major manifestations of the disease. Contemporary therapy is based upon the restriction of dietary phenylalanine intake through the reduction of dietary protein. Under this regimen, synthetic medical foods with limited phenylalanine content may be administered whole or dissolved in water or apple juice. The tablets contain ascorbic acid to maintain BH₄ synthesis.

**History of tetrahydrobiopterin responsiveness in phenylketonuria**

Individuals with inherited PAH deficiency have normal biotin content in blood and urine, but Kure et al reported that oral administration of additional BH₄ to some individuals with mild hyperphenylalaninemia led to a significant reduction in blood phenylalanine levels without altering dietary phenylalanine content. Several other investigators have subsequently confirmed this observation. The basis of BH₄ responsiveness may be related to different molecular mechanisms. Increased liver BH₄ content may simply stimulate the activity of mutant partially active PAH enzyme or it may act as a chemical chaperone to stabilize mutant PAH monomers. Proof of this latter mechanism is provided by investigation of other small molecules that act as chaperones to stabilize mutant PAH. Some specific PAH mutations are known to affect the affinity of the PAH enzyme for its biotin cofactor. In patients with these specific mutations, oral biotin administration may overcome this block and restore enzymatic activity. In reality, only a few such mutations have been shown to be often (but not invariably) associated with BH₄ responsiveness in PKU patients while other mutations, such as the R408W mutation, are consistently associated with nonresponsiveness. BH₄ responsiveness in an individual PKU patient cannot always be accurately predicted from their PAH genotype.

**Clinical trials of sapropterin in phenylketonuria**

After the discovery that some PKU patients could benefit from BH₄ supplementation, few patients were able to avail themselves of this treatment option because the worldwide supply of BH₄ was limited and detailed pharmacokinetic studies had not been performed. In the USA, BH₄ was approved by the FDA only for use as an investigational drug. To overcome this problem, BioMarin Corporation (Novato, CA) initiated a specific effort to develop and intensively study sapropterin dihydrochloride ((6R)-2-amino-6-[(1R, 2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(3H)-pteridinone dihydrochloride, Figure 2), a biologically active synthetic form of BH₄ in subjects with PKU. Sapropterin dihydrochloride is supplied in airtight blister packs as 100 mg tablets that may be administered whole or dissolved in water or apple juice. The tablets contain ascorbic acid to maintain BH₄ synthesis.
the reduction status of sapropterin and allowing storage at room temperature. In patients with PKU who are responsive to sapropterin, daily oral administration of sapropterin leads to a sustained decrease in blood phenylalanine levels without alteration of dietary phenylalanine intake. The mean half-life of elimination of sapropterin from the blood is 6.7 (range 3–17) hours in PKU patients.23 The specific mechanism of elimination for sapropterin dihydrochloride has not been published, but abundant data concerning the fate of orally administered natural BH4 in humans and animals demonstrate that BH4 is quickly sequestered in the liver or excreted in urine.26

To determine the actual prevalence of BH4 responsiveness, an open-label, screening study was performed in 490 individuals with PKU enrolled at 30 treatment centers in the US and Europe.27 Blood phenylalanine levels were greater than 450 µM (normal range 35–150 µM) in all subjects at the beginning of the study, signifying less than ideal disease control on standard dietary therapy. Sapropterin dihydrochloride, 10 mg/kg body weight, was administered orally once per day for eight days. Subjects were instructed not to alter their typical dietary protein intake during the study. Blood phenylalanine levels were measured prior to sapropterin treatment and again on day 8, and “BH4 responsiveness” was defined as a 30% reduction in blood phenylalanine. Overall, 20% of study subjects (96/485 subjects who completed the entire eight-day trial) responded to sapropterin treatment. Among all responders, blood phenylalanine levels decreased to 391.8 ± 185.3 µM (mean ± 1 standard deviation) after eight days of sapropterin administration. When stratified by blood phenylalanine level prior to initiating therapy, a higher proportion of individuals with mild PKU responded to sapropterin. In these subjects, 54% and 24% with initial blood levels of 450–600 µM or 600–900 µM, respectively, responded to sapropterin. Somewhat surprisingly, 10% of subjects with initial phenylalanine levels greater than 900 µM also responded, with at least a 30% reduction in blood phenylalanine. For standard dietary therapy in young children with PKU, the target range for blood phenylalanine during treatment is commonly 120–360 µM. Approximately 10% of subjects with PKU in this screening trial achieved a reduction in blood phenylalanine to the accepted treatment target range on sapropterin alone without any change in dietary phenylalanine intake. An additional 10% of the study population achieved a clinically significant reduction in blood phenylalanine, but phenylalanine levels remained above 360 µM. No severe adverse effects of sapropterin therapy were reported.

Once the prevalence of BH4-responsive hyperphenylalaninemia was established, a Phase III, randomized, double-blind, placebo-controlled trial28 was initiated to evaluate fully the efficacy of sapropterin treatment. Sapropterin-responsive subjects identified in the Phase II trial were randomly assigned to receive either sapropterin 10 mg/kg once per day or placebo for six weeks. At the end of the trial, no serious adverse events were reported in either study group, and the incidence of minor events was equal in the two study groups. By the end of the six-week trial, blood phenylalanine in the sapropterin treatment group (n = 40 subjects) decreased from 842.7 ± 299.6 µM to 606.9 ± 377.0 µM on average. The mean change in blood phenylalanine was −235.9 ± 257.0 µM over six weeks on sapropterin compared with a change of only +2.9 ± 239.5 µM in the control group (n = 47 subjects). The estimated difference between the two groups was −245 ± 52.5 µM (P = 0.0002). Over the course of the study, 44% of subjects on sapropterin had a sustained reduction in blood phenylalanine greater than 30% from baseline compared with only 9% of controls. Prior to initiation of the trial, only 17% of subjects exhibited blood phenylalanine levels below 600 µM. In the sapropterin treatment group, 54% of subjects achieved blood phenylalanine below 600 µM. Blood phenylalanine decreased to less than 360 µM in 32% of subjects.

BH4 responsiveness has been predicted to occur only in patients who carry at least one mutant PAH allele that yields some residual PAH enzyme activity.29 Among sapropterin-responsive subjects in the Phase III trial, PAH genotyping was available for 17 subjects, and non-null PAH mutations were detected on at least one allele in 16 of 17 subjects. However, in the seventeenth subject, both PAH alleles carried severe mutations that would not appear to permit expression of residual PAH activity, yet this subject responded to sapropterin treatment. Sapropterin responsiveness in the study subjects was not linked to any specific PAH mutation. Two reviews suggest that genotype can predict to some degree whether a patient with PKU will be responsive to BH4, but that ultimately only BH4 challenge will fully ascertain BH4 responsiveness.23,24
In a third clinical trial, 80 sapropterin-responsive subjects participated in a multicenter, open-label extension study. The initial phase of the trial was a forced dose titration study, with subjects receiving doses of 5, 20, and 10 mg/kg/day of sapropterin consecutively for two weeks each. This was followed by a four-week period of 10 mg/kg/day and then a 12-week fixed dose extension. In the last phase, subjects received one of three different sapropterin doses (5, 10, or 20 mg/kg/day) based upon their individual responses in the dose titration phase of the study. In the first phase, although plasma phenylalanine levels decreased from week 0 at all sapropterin doses, a dose-response relationship was demonstrated, with significantly lower plasma phenylalanine levels on average during treatment with 10 or 20 mg/kg/day than when the subjects received only 5 mg/kg/day. During the fixed-dose extension phase, six subjects (8%) responded to 5 mg/kg/day, while 37 subjects (46%) received 10 mg/kg/day, and 37 subjects (46%) received 20 mg/kg/day. The choice of dose and the reduction in phenylalanine levels achieved by 22 weeks clearly reflect a dichotomy in the severity of PKU in the study subjects. Individuals with higher phenylalanine levels at baseline required more drug to effect a decrease in blood phenylalanine, and the drop in phenylalanine level achieved was not as satisfactory as that demonstrated by subjects responding to either 5 or 10 mg/kg/day. Overall, plasma phenylalanine decreased by 190.5 \( \mu M \) (±355.7) in all dose groups after 22 weeks of drug. The mean plasma phenylalanine level at the end of 22 weeks in the 20 mg/kg dose group was 895.7 (±407.2) \( \mu M \) while mean phenylalanine levels in the 5 and 10 mg/kg dose groups were 437.8 (±260.5) \( \mu M \) and 449.9 (±193.1) \( \mu M \), respectively. Individuals with a lower baseline phenylalanine level (a measure of dietary phenylalanine tolerance) showed greater responsiveness to the drug. Only 50%, 49%, and 42% of subjects in the 5, 10, and 20 mg/kg dose groups, respectively, achieved a 30% decrease in plasma phenylalanine from baseline at the end of the 22 weeks. Recall that all study subjects had demonstrated a 30% reduction in plasma phenylalanine over eight days in the initial screening study. Unintended changes in dietary protein intake during the course of the trials (further protein restriction during the screening trial or liberalization of dietary protein intake during the extension trial) would have affected these results. There were no minor or severe adverse events attributable to sapropterin treatment in the trial. This extension study demonstrates that sapropterin treatment may safely reduce plasma phenylalanine concentrations in a dose-dependent manner in BH4-responsive individuals. Furthermore, empiric use of the drug for one month or more may be needed.

The effectiveness of sapropterin treatment has also been examined in 90 children aged 4–12 years with PKU while they continued on a protein-restricted diet. Of these subjects, 56% experienced a 30% reduction in blood phenylalanine levels after eight days of sapropterin treatment. After the challenge period, all responders were offered participation in a placebo-controlled trial during which dietary phenylalanine intake was gradually increased. In the group receiving sapropterin, dietary phenylalanine tolerance doubled on average, with no significant increase in blood phenylalanine levels in comparison with phenylalanine tolerance prior to sapropterin treatment, while dietary phenylalanine tolerance increased only slightly in the placebo group. Again, no significant safety issues were revealed.

Based on the accumulated study data, the FDA approved sapropterin dihydrochloride for clinical use in December 2007. Marketing authorization for sapropterin has subsequently been granted in Japan (July 2008) and Europe (December 2008), and is under expedited review in Canada. In Europe, sapropterin has been licensed for use in children with PAH deficiency over the age of four years, and also in individuals of all ages with hyperphenylalaninemia due to congenital BH4 deficiency. In the US, sapropterin treatment is approved in all age groups and in pregnant women, even though sapropterin has not been formally studied in children under four years age or during pregnancy. Limited experience with administration of other commercially available forms of BH4 during pregnancy suggests that no adverse effects are to be expected. In the case of the pregnant woman with BH4-responsive PKU, the well documented risks to the fetus associated with maternal hyperphenylalaninemia likely outweigh any putative risks of sapropterin treatment. Still, these issues deserve further study and BioMarin has initiated a voluntary registry system to accumulate data on the use of sapropterin in young children and during pregnancy.

**Post-approval clinical use of sapropterin**

Now that sapropterin has gained FDA approval, the task ahead is to determine which PKU patients will benefit most from this novel therapeutic approach and how to best introduce this medication into a specific patient’s dietary treatment regimen. Sapropterin has been formally proven in research studies to lower blood phenylalanine levels in individuals who are responsive, but limited data are available concerning the effect of sapropterin treatment on actual protein tolerance. Can the sapropterin-treated patient safely increase their dietary protein intake and maintain blood phenylalanine levels within a designated treatment range? Also, long-term safety and cognitive
outcome should be evaluated in patients who will probably be treated with sapropterin for many years.

The determination of whether a specific patient with PKU is truly BH₄-responsive is clearly key to the decision about adding sapropterin to the patient’s treatment regimen. To some degree, the definition of “responsiveness” is an arbitrary one. For the purposes of the screening study, responsiveness was defined as a 30% decrease in plasma phenylalanine after an eight-day trial of oral sapropterin at 10 mg/kg/day. As we have seen, subsequent evaluations have revealed both false-positive and false-negative results from this screening procedure. Some individuals who met criteria for responsiveness during the screening trial subsequently did not maintain a therapeutic effect from sapropterin over the longer term. Some individuals who did not meet criteria for responsiveness with a sapropterin dose of 10 mg/kg/day were later found to be responsive to the higher dose of 20 mg/kg/day. It has been suggested that BH₄ responsiveness would require a patient with PKU to carry at least one PAH mutant allele that allows for residual enzyme activity. However, in the clinical trial, a few individuals who were found to be sapropterin-responsive carried PAH mutations that were predicted to yield severe PAH deficiency. A recent comprehensive review suggests that genotype can predict to some degree whether a patient with PKU will be responsive to BH₄, but that ultimately only BH₄ challenge will fully ascertain BH₄ responsiveness.

In addition to the eight-day screening trials employed in the clinical trial, several other BH₄ challenge protocols have been described in the literature, and these have recommended differing BH₄ doses, different durations of challenge, determination of blood phenylalanine levels at different times, varying percentage reductions in blood phenylalanine required to define BH₄ responsiveness and, in some cases, challenging the subject with a standardized amount of dietary phenylalanine along with BH₄. This topic has been reviewed. Recent published data have revealed that the decrease in blood phenylalanine following a single BH₄ dose obeys a first-order kinetic model only over the first eight hours after BH₄ administration. Accordingly, a single BH₄ loading test (20 mg/kg) with monitoring of blood phenylalanine at 0, 8, 12, and 24 hours has been proposed as an evaluation of responsiveness. If blood phenylalanine dropped more than 20% in the short term, then a several-week trial with BH₄ dose adjustment to maintain optimal phenylalanine levels would be warranted.

A rational algorithm for testing BH₄ responsiveness in a routine clinical setting has been proposed and a similar protocol has been endorsed by clinicians in Europe. This algorithm evaluates both the short-term response to BH₄ administration (allowing for upward adjustment of dietary phenylalanine intake if blood phenylalanine levels fall dramatically after BH₄ treatment) and the longer-term efficacy of sapropterin treatment. In this algorithm, blood phenylalanine is measured prior to sapropterin administration and on days 1, 7, 14, and 28 following sapropterin 20 mg/kg/day. The sapropterin dose may be decreased or dietary phenylalanine increased if blood phenylalanine levels decrease below the target range. Responsiveness is not defined by any specific percentage decrease in phenylalanine but rather by whether the decrease in phenylalanine is thought by the clinician and patient to be clinically meaningful. Continued sapropterin treatment is warranted if blood phenylalanine levels are lowered into a specific target range defined by clinician and patient and is particularly relevant if dietary phenylalanine restriction can be relaxed without increasing blood phenylalanine. This testing algorithm allows for the individualization of therapy and flexibility in the assessment of BH₄ responsiveness.

Cost of sapropterin

The cost of sapropterin therapy versus the PKU diet must also be considered. As a drug with an orphan product designation, the costs of drug development for sapropterin are distributed among a relatively small patient population. The cost of daily sapropterin therapy at the highest dose of 20 mg/kg/day is US $100,000 to $150,000 for the average adult patient versus the cost of the phenylalanine-restricted diet, including the use of medical foods, which is typically US $15,000 to $20,000 per year. The PKU patient and their clinician must consider these factors when deciding whether to employ sapropterin therapy.

Conclusions

The systematic evaluation of sapropterin responsiveness in a PKU population and the subsequent commercial availability of a validated form of BH₄ have now provided a new therapeutic option for phenylketonuria. As discussed, continuance of strict dietary therapy throughout life is recommended but is practically difficult. Compliance with this recommendation in adults is often poor. For a subset of individuals with PKU, sapropterin will be essential as sole therapy. For other patients, sapropterin treatment may not completely eliminate the need for dietary therapy, but may increase a patient’s dietary protein tolerance, allowing a significant improvement in daily quality of life. The introduction of sapropterin for widespread clinical use represents an exciting time in the evolution of therapy for PKU.

Disclosure

The author reports no conflict of interest in this work.
References


